These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. [Treatment for low-risk myelodysplastic syndromes]. Morita Y Rinsho Ketsueki; 2018; 59(10):2050-2057. PubMed ID: 30305508 [TBL] [Abstract][Full Text] [Related]
5. Hypomethylating agents and other novel strategies in myelodysplastic syndromes. Garcia-Manero G; Fenaux P J Clin Oncol; 2011 Feb; 29(5):516-23. PubMed ID: 21220589 [TBL] [Abstract][Full Text] [Related]
6. Diagnosis and Treatment of Myelodysplastic Syndromes: A Review. Sekeres MA; Taylor J JAMA; 2022 Sep; 328(9):872-880. PubMed ID: 36066514 [TBL] [Abstract][Full Text] [Related]
7. Optimal sequencing of treatments for patients with myelodysplastic syndromes. Itzykson R; Fenaux P Curr Opin Hematol; 2009 Mar; 16(2):77-83. PubMed ID: 19468268 [TBL] [Abstract][Full Text] [Related]
8. Clinical management of myelodysplastic syndromes with interstitial deletion of chromosome 5q. Nimer SD J Clin Oncol; 2006 Jun; 24(16):2576-82. PubMed ID: 16735711 [TBL] [Abstract][Full Text] [Related]
9. Myelodysplastic syndromes: a review of therapeutic progress over the past 10 years. Feld J; Belasen A; Navada SC Expert Rev Anticancer Ther; 2020 Jun; 20(6):465-482. PubMed ID: 32479130 [TBL] [Abstract][Full Text] [Related]
10. Recent advances in the treatment of lower-risk non-del(5q) myelodysplastic syndromes (MDS). Almeida A; Fenaux P; List AF; Raza A; Platzbecker U; Santini V Leuk Res; 2017 Jan; 52():50-57. PubMed ID: 27883945 [TBL] [Abstract][Full Text] [Related]
11. Relationship of treatment-related cytopenias and response to lenalidomide in patients with lower-risk myelodysplastic syndromes. Sekeres MA; Maciejewski JP; Giagounidis AA; Wride K; Knight R; Raza A; List AF J Clin Oncol; 2008 Dec; 26(36):5943-9. PubMed ID: 19018091 [TBL] [Abstract][Full Text] [Related]
12. Novel therapeutic strategies: hypomethylating agents and beyond. Santini V Hematology Am Soc Hematol Educ Program; 2012; 2012():65-73. PubMed ID: 23233562 [TBL] [Abstract][Full Text] [Related]
13. Myelodysplastic syndromes: 2015 Update on diagnosis, risk-stratification and management. Garcia-Manero G Am J Hematol; 2015 Sep; 90(9):831-41. PubMed ID: 26294090 [TBL] [Abstract][Full Text] [Related]
14. Treatment options for lower-risk myelodysplastic syndromes. Where are we now? Volpe VO; Komrokji RS Ther Adv Hematol; 2021; 12():2040620720986641. PubMed ID: 33505645 [TBL] [Abstract][Full Text] [Related]
15. Selection of patients with myelodysplastic syndromes from a large electronic medical records database and a study of the use of disease-modifying therapy in the United States. Ma X; Steensma DP; Scott BL; Kiselev P; Sugrue MM; Swern AS BMJ Open; 2018 Jul; 8(7):e019955. PubMed ID: 30037860 [TBL] [Abstract][Full Text] [Related]
16. Myelodysplastic syndromes: Contemporary review and how we treat. Gangat N; Patnaik MM; Tefferi A Am J Hematol; 2016 Jan; 91(1):76-89. PubMed ID: 26769228 [TBL] [Abstract][Full Text] [Related]
17. Established and novel agents for myelodysplastic syndromes. Sekeres MA; Gerds AT Hematology Am Soc Hematol Educ Program; 2014 Dec; 2014(1):82-9. PubMed ID: 25696839 [TBL] [Abstract][Full Text] [Related]
18. The lower risk MDS patient at risk of rapid progression. Mittelman M; Oster HS; Hoffman M; Neumann D Leuk Res; 2010 Dec; 34(12):1551-5. PubMed ID: 20573398 [TBL] [Abstract][Full Text] [Related]